117 related articles for article (PubMed ID: 36208091)
1. High MutS homolog 2 expression predicts poor prognosis and is related to immune infiltration in endometrial carcinoma.
Lu X; Ying Y; Zhang W; Li R; Zhang J
Cell Biol Int; 2023 Jan; 47(1):201-215. PubMed ID: 36208091
[TBL] [Abstract][Full Text] [Related]
2. Analysis of the Expression and Prognostic Value of MSH2 in Pan-Cancer Based on Bioinformatics.
Qiu W; Ding K; Liao L; Ling Y; Luo X; Wang J
Biomed Res Int; 2021; 2021():9485273. PubMed ID: 34859104
[TBL] [Abstract][Full Text] [Related]
3. DNA mismatch repair-related protein loss as a prognostic factor in endometrial cancers.
Kato M; Takano M; Miyamoto M; Sasaki N; Goto T; Tsuda H; Furuya K
J Gynecol Oncol; 2015 Jan; 26(1):40-5. PubMed ID: 25310854
[TBL] [Abstract][Full Text] [Related]
4. Reduced expression of mutS homolog 2 and mutL homolog 1 affects overall survival in laryngeal squamous cell carcinoma patients: Investigation into a potential cause.
Gong HL; Shi Y; Shi Y; Wu CP; Cao PY; Zhou L; Xu C
Oncol Rep; 2013 Sep; 30(3):1371-9. PubMed ID: 23787767
[TBL] [Abstract][Full Text] [Related]
5. [Expression and clinical significance of MMR protein and MLH1 promoter methylation testing in endometrial cancer].
Jin W; Wang LQ; Liu Y; Liu AJ
Zhonghua Fu Chan Ke Za Zhi; 2018 Dec; 53(12):823-830. PubMed ID: 30585020
[No Abstract] [Full Text] [Related]
6. MLH1 and MSH2 protein expression as a pre-screening marker in hereditary and non-hereditary endometrial hyperplasia and cancer.
Berends MJ; Hollema H; Wu Y; van Der Sluis T; Mensink RG; ten Hoor KA; Sijmons RH; de Vries EG; Pras E; Mourits MJ; Hofstra RM; Buys CH; Kleibeuker JH; van Der Zee AG
Int J Cancer; 2001 May; 92(3):398-403. PubMed ID: 11291077
[TBL] [Abstract][Full Text] [Related]
7. Microsatellite Instability in Endometrial Carcinoma by Immunohistochemistry, Association with Clinical and Histopathologic Parameters.
Hashmi AA; Mudassir G; Hashmi RN; Irfan M; Asif H; Khan EY; Abu Bakar SM; Faridi N
Asian Pac J Cancer Prev; 2019 Sep; 20(9):2601-2606. PubMed ID: 31554352
[TBL] [Abstract][Full Text] [Related]
8. TMEM41A overexpression correlates with poor prognosis and immune alterations in patients with endometrial carcinoma.
Shi K; Liu XL; Guo Q; Zhang YQ; Fan ST; Dai L; Jiang N; Li D
PLoS One; 2023; 18(7):e0285817. PubMed ID: 37478120
[TBL] [Abstract][Full Text] [Related]
9. Hypomethylation of mismatch repair genes MLH1 and MSH2 is associated with chemotolerance of breast carcinoma: Clinical significance.
Dasgupta H; Islam S; Alam N; Roy A; Roychoudhury S; Panda CK
J Surg Oncol; 2019 Jan; 119(1):88-100. PubMed ID: 30481381
[TBL] [Abstract][Full Text] [Related]
10. MSH2/BRCA1 expression as a DNA-repair signature predicting survival in early-stage lung cancer patients from the IFCT-0002 Phase 3 Trial.
Levallet G; Dubois F; Fouret P; Antoine M; Brosseau S; Bergot E; Beau-Faller M; Gounant V; Brambilla E; Debieuvre D; Molinier O; Galateau-Sallé F; Mazieres J; Quoix E; Pujol JL; Moro-Sibilot D; Langlais A; Morin F; Westeel V; Zalcman G
Oncotarget; 2017 Jan; 8(3):4313-4329. PubMed ID: 28008145
[TBL] [Abstract][Full Text] [Related]
11. CircWDR26 regulates endometrial carcinoma progression via miR-212-3p-mediated typing genes MSH2.
Lei TX; He DJ; Cao J; Lv WG
Eur J Med Res; 2022 Jul; 27(1):135. PubMed ID: 35897048
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathologic and familial characteristics of endometrial carcinoma with multiple primary carcinomas in relation to the loss of protein expression of MSH2 and MLH1.
Maruyama A; Miyamoto S; Saito T; Kondo H; Baba H; Tsukamoto N
Cancer; 2001 Jun; 91(11):2056-64. PubMed ID: 11391585
[TBL] [Abstract][Full Text] [Related]
13. High expression of S100A2 predicts poor prognosis in patients with endometrial carcinoma.
Zhang Q; Xia T; Qi C; Du J; Ye C
BMC Cancer; 2022 Jan; 22(1):77. PubMed ID: 35042454
[TBL] [Abstract][Full Text] [Related]
14. Risk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome: a cohort study.
Kempers MJ; Kuiper RP; Ockeloen CW; Chappuis PO; Hutter P; Rahner N; Schackert HK; Steinke V; Holinski-Feder E; Morak M; Kloor M; Büttner R; Verwiel ET; van Krieken JH; Nagtegaal ID; Goossens M; van der Post RS; Niessen RC; Sijmons RH; Kluijt I; Hogervorst FB; Leter EM; Gille JJ; Aalfs CM; Redeker EJ; Hes FJ; Tops CM; van Nesselrooij BP; van Gijn ME; Gómez García EB; Eccles DM; Bunyan DJ; Syngal S; Stoffel EM; Culver JO; Palomares MR; Graham T; Velsher L; Papp J; Oláh E; Chan TL; Leung SY; van Kessel AG; Kiemeney LA; Hoogerbrugge N; Ligtenberg MJ
Lancet Oncol; 2011 Jan; 12(1):49-55. PubMed ID: 21145788
[TBL] [Abstract][Full Text] [Related]
15. Gene expression of the mismatch repair gene MSH2 in primary colorectal cancer.
Jensen LH; Kuramochi H; Crüger DG; Lindebjerg J; Kolvraa S; Danenberg P; Danenberg K; Jakobsen A
Tumour Biol; 2011 Oct; 32(5):977-83. PubMed ID: 21732224
[TBL] [Abstract][Full Text] [Related]
16. miR-149-3p Is a Potential Prognosis Biomarker and Correlated with Immune Infiltrates in Uterine Corpus Endometrial Carcinoma.
Lu X; Jing L; Liu S; Wang H; Chen B
Int J Endocrinol; 2022; 2022():5006123. PubMed ID: 35719192
[TBL] [Abstract][Full Text] [Related]
17. MSH2 promoter hypermethylation in circulating tumor DNA is a valuable predictor of disease-free survival for patients with esophageal squamous cell carcinoma.
Ling ZQ; Zhao Q; Zhou SL; Mao WM
Eur J Surg Oncol; 2012 Apr; 38(4):326-32. PubMed ID: 22265839
[TBL] [Abstract][Full Text] [Related]
18. Universal screening for Lynch syndrome in endometrial cancers: frequency of germline mutations and identification of patients with Lynch-like syndrome.
Dillon JL; Gonzalez JL; DeMars L; Bloch KJ; Tafe LJ
Hum Pathol; 2017 Dec; 70():121-128. PubMed ID: 29107668
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of JAK3 promoter methylation and mRNA expression in clear cell renal cell carcinoma.
Long Q; Huang C; Huang J; Meng Q; Cheng Y; Li Y; He L; Chen M; Zhang C; Wang X; Zhu W; Peng J; Shi D; Zheng F; Dong P; Deng W
J Adv Res; 2022 Sep; 40():153-166. PubMed ID: 36100323
[TBL] [Abstract][Full Text] [Related]
20. Microsatellite Instability and Altered Expressions of MLH1 and MSH2 in Gastric Cancer.
Haron NH; Mohamad Hanif EA; Abdul Manaf MR; Yaakub JA; Harun R; Mohamed R; Mohamed Rose I
Asian Pac J Cancer Prev; 2019 Feb; 20(2):509-517. PubMed ID: 30803214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
